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A B S T R A C T
Background
Radiotherapy has been proposed as a treatment to prevent new vessel growth in people with neovascular age-relatedmacular degeneration
(AMD).
Objectives
The aim of this review was to examine the effects of radiotherapy on neovascular AMD.
Search strategy
We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (which contains the Cochrane Eyes and Vision Group
trials register) on The Cochrane Library Issue 2, 2004, MEDLINE (1966 to May 2004), EMBASE (1980 to June 2004) and LILACS
(Latin American and Caribbean Health Sciences Literature Database) (May 2004). We also wrote to investigators of trials included in
the review to ask if they were aware of any other studies.
Selection criteria
We included all randomised controlled trials in which radiotherapy was compared to another treatment, sham treatment, low dosage
irradiation or no treatment in people with subfoveal choroidal neovascularisation secondary to AMD.
Data collection and analysis
Two reviewers independently extracted the data. Relative risks were combined using a random effects model. The percentage of the
variability in effect estimates that was due to heterogeneity, rather than sampling error, was estimated using I2.
Main results
Eleven trials randomising a total of 1078 people were included in this review. All trials used a similar method of delivering the
radiotherapy treatment (external beam).Dosage ranged from7.5 to 24Gy.Most trials found effects (not always significant) that favoured
treatment. However, there was considerable inconsistency in the results between trials (I2 > 50%). As only 11 trials were included in the
review and only some of these trials provided data for each outcome our ability to determine the causes of the heterogeneity between
trials was limited. Subgroup analyses did not reveal any statistically significant interactions although with small numbers of trials in
each subgroup (range two to four) this was not surprising. There was some indication that trials with no sham irradiation reported a
greater effect of treatment as did trials with a greater percentage of participants with classic choroidal neovascularisation.
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Authors’ conclusions
This review currently does not provide evidence that external beam radiotherapy is an effective treatment for neovascular AMD. If
further trials are to be considered to evaluate radiotherapy in AMD then adequate masking of the control group must be considered.
Given the recent evidence that most lesions are amenable to treatment with photodynamic therapy if identified at a small lesion size,
trials evaluating radiotherapy against photodynamic therapy are warranted.
P L A I N L A N G U A G E S U M M A R Y
Radiotherapy for neovascular age-related macular degeneration
The macula is the central area of the retina used for detailed vision. Age-related macular degeneration (AMD) is the leading cause
of blindness in the developed world, particularly in the elderly, and can be associated with new blood vessel growth under the retina
of the eye, termed subfoveal choroidal neovascularisation (CNV). The present treatment of choice is photodynamic therapy (PDT)
with verteporfin. Radiotherapy has been proposed to prevent new vessel growth. This review found that most trials showed effects (not
always significant) that favoured treatment with radiotherapy but with inconsistencies in the results. Radiotherapy has potential risks
of systemic morbidity and exposure to the fellow eye.
B A C K G R O U N D
Introduction
The macula, the central area of the retina, is used for detailed
vision such as reading, recognising faces and driving. Age-related
macular degeneration (AMD) is the leading cause of blindness
in the developed world. It is difficult to get a clear definition of
AMD. The term ’age-related’ is used partly due to its unknown
pathogenesis. It is believed that both genetic and environmental
factors play a significant role in the development of the disease.
From a clinical perspective, AMD primarily affects the macular
region. The term ’degeneration’ is used to distinguish AMD from
other genetic macular dystrophies which run in families and those
where there is a clear environmental cause such as an infection or
trauma.
There are several signs appearing in the retina that are associated
with increasing age and increased risk of developing age-related
macular degeneration. These signs, known as age-related macu-
lopathy (ARM), include the presence of drusen (yellow spots be-
neath the retina), pigmentary disturbance and small focal areas of
atrophy. In general, ARM is not associated with significant visual
loss. Some people with ARM will go on to develop AMD.
Epidemiology
The prevalence of ARM is about 30% in the over 70 age group.
The reported prevalence of AMD varies significantly between sev-
eral large scale epidemiological studies, partly due to the inconsis-
tency in terminology used. It is, however, clearly increasing with
age. Although it was reported that females are more likely to suf-
fer from AMD, after correction for age and life expectancy the
gender difference is not significant (Evans 2001). In the UK, ap-
proximately 30,000 people are registered blind or partially sighted
every year, half of whom will have macular degeneration (Evans
1995).
Presentation
Classification of AMD has been controversial. Currently accepted
definitions distinguish those people who have geographic atro-
phy (large area of atrophy centred in the macula) and those with
choroidal neovascularisation (CNV). This review is concerned
with treatment for neovascular AMD.
In neovascular (wet) AMD, CNV develops beneath the retina. In
the initial phase the CNV might cause visual distortion due to
leakage of fluid into the surrounding retina. At this stage the reti-
nal function is only mildly affected and the CNV is potentially
reversible. However, the CNV may leak serum lipid and protein
leading to exudation and significant swelling of the retina. The
CNV may bleed and the haemorrhages may be toxic. Both ex-
udation and haemorrhages induce a scarring response. These are
associated with extensive damage to the architecture of the retina-
retinal pigment epithelium-choroid complex, leading to signifi-
cant visual loss.
Choroidal neovascularisation is defined as classic or occult accord-
ing to its appearance on fluorescein angiography, where fluores-
cent dye is injected intravenously and imaged as it passes through
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the blood vessels of the eye. Classic membranes are clearly delin-
eated and can be seen at the early frames of the angiogram. Occult
membranes present as either late leakage, which cannot be seen in
the early frames, or fibrovascular pigment epithelial detachment.
Most lesions have both classic and occult components.
Treatment options
The Macular Photocoagulation Study Group (MPSG 1994) has
shown that laser photocoagulation of classic extrafoveal and
juxtafoveal CNV (those not directly underneath the fovea at the
centre of themacula) could delay the loss of vision. However,most
patients present with subfoveal CNV (those where a component
of the CNV extends underneath the fovea) and whilst photocoag-
ulation can limit the extent of the subsequent visual loss it causes
immediate loss of central vision due to the concurrent destruction
of the overlying retina. Laser therapy for subfoveal CNV is rarely
performed in practice.
Photodynamic therapy (PDT) has been investigated to treat CNV
without affecting the retina. Photoreactive chemicals are injected
into the patient and irradiated with light as they pass through the
CNV.This light is strong enough to activate the chemicals, causing
them to emit free radicals that destroy the blood vessels, but is
not strong enough to cause damage to the overlying retina. The
TAP Study Group (Bressler 2001; TAP Study 1999) has shown
that PDT is effective for patients with 100% classic CNV. The
effectiveness for predominantly classic, but not 100%classic CNV,
is more debatable. It is not effective for predominantly occult
CNV. A systematic review of PDT for AMD is published on The
Cochrane Library (Wormald 2004).
Radiotherapy is commonly used in oncology. The use of radiother-
apy in non-neoplastic diseases is increasingly common. It is be-
lieved that it can preferentially damage dividing and fast growing
cellsmore than normal supporting cells. In rats, photoreceptor cell
death is not seen at doses less than 10 Gy and the retinal pigment
epithelial cell loss does not occur under 20 Gy in single-fraction.
There is also evidence to suggest that fractionation of irradiation
greatly reduces the toxicity but preserves the DNA-damaging ef-
fects in rapidly dividing cells. Clinical experience suggested that
cumulative doses of up to 25 Gy cause no damage to the retina
or optic nerve. As the endothelial cells in CNV are dividing it is
possible that radiotherapy can stop the growth of CNV without
significant damage to the retina.
Rationale for a systematic review
There are several randomised controlled trials of radiotherapy
for neovascular AMD using different dosage and fractionation
schemes. The aim of this review was to systematically assess the
results of these studies with a view to providing an overall estimate
of treatment effect.
O B J E C T I V E S
The aim of this review was to examine the effects of radiotherapy
on neovascular AMD.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised controlled trials (RCTs).
Types of participants
We included trials in which participants were people with
choroidal neovascularisation (CNV) secondary to AMD as de-
fined by the study investigators.
Types of interventions
We included studies in which radiotherapy, no matter how it was
delivered, was compared to another treatment, low dosage irradi-
ation, sham treatment or no treatment.
Types of outcome measures
Primary outcomes
The primary outcome for this review was loss of visual acuity. We
considered two measures of loss of visual acuity - three or more
lines lost on a logMAR chart (equivalent to doubling of visual
angle) and six or more lines lost (equivalent to quadrupling of
visual angle). We also considered mean visual acuity and change
in visual acuity as a continuous score.
Secondary outcomes
The secondary outcomes for this review were:
• measures of contrast sensitivity;
• new vessel growth;
• quality of life measures - any validated measurement scale
which aims to measure the impact of visual function loss on
quality of life of participants;
• any adverse outcomes as reported in trials.
Follow up
We measured outcomes at 6, 12 and 24 months after radiation
treatment.
3Radiotherapy for neovascular age-related macular degeneration (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Search methods for identification of studies
Electronic searches
Trials were identified from the Cochrane Central Register of Con-
trolled Trials (CENTRAL) (which contains the Cochrane Eyes
and Vision Group trials register) on The Cochrane Library, MED-
LINE, EMBASE and LILACS (Latin American and Caribbean
Health Sciences Literature Database). There were no language re-
strictions in the searches.
See: Appendices for details of search strategies for each database.
Searching other resources
We contacted the investigators of the trials included in this review
for information about further trials.We searched the reference lists
of relevant studies for further trial reports. We did not perform
manual searches of conference proceedings or journals.
Data collection and analysis
Finding the trials
Two reviewers independently scanned the titles and abstracts re-
sulting from the searches.We obtained full copies of all potentially
or definitely relevant articles. Two reviewers assessed the full copies
according to the ’Criteria for considering studies for this review’.
Only articles meeting these criteria were assessed for quality.
Assessment of methodological quality
Two reviewers independently assessed study quality according to
methods set out in Section 6 of the Cochrane Reviewers’ Hand-
book. The reviewers were not masked to any trial details during
the assessment. Four parameters of quality were considered when
grading the articles: allocation concealment and method of allo-
cation to treatment; masking of providers and recipients of care;
masking of outcome assessment; and completeness of follow up.
We graded each parameter of trial quality: A - adequate; B - un-
clear; or C - inadequate. We resolved disagreement between the
reviewers on assessments by discussion. We contacted the trial au-
thors for clarification on any parameter graded B - unclear. We ex-
cluded any trial scoring C - inadequate on allocation concealment
and method of allocation to treatment.
Data collection
Two reviewers independently extracted data using a form devel-
oped by the Cochrane Eyes and Vision Group. Discrepancies were
resolved by discussion. One reviewer entered data into RevMan
4.2 using the double data-entry facility to check for errors.
Data synthesis
The primary outcome of visual acuity loss was assessed at 6, 12
and 24 months. We used two outcomes, loss of three or more lines
on a logMAR chart (equivalent to a doubling of the visual angle)
and loss of six or more lines (quadrupling of the visual angle). As
the proportion of people experiencing this outcome was high in
the control group (more than 10%) we used the relative risk as
our effect measure. Not all trials reported visual acuity outcomes
in this dichotomous format. We contacted investigators for data
but these requests were not successful. We, therefore, also included
mean visual acuity and change in visual acuity as a continuous
score.
There was considerable statistical heterogeneity between studies.
However, the amount of heterogeneity varied with the outcome.
We have included the pooled analyses and I2 estimates on the
graphs for information but have not reported the pooled results in
the abstract. We used a random effects model to combine results.
Not all of the trials reported data for all outcomes. This meant
that our options for exploring the sources of heterogeneity were
limited. In our protocol we specified three factors as of interest for
subgroup analyses (method of delivery, dosage and type of CNV).
All trials used the same method of delivery.Table 1 shows the
details of dosage in the trials and Table 2 shows the details of CNV.
During the course of doing the review we identified one additional
aspect of study design as of interest for subgroup analysis. This
was whether or not sham irradiation was carried out in the control
group.
Using these factors we performed stratified analyses, the purpose of
which was to determine whether the outcome varied significantly
with type of explanatory variable.We used data from the 12month
follow-up and divided the trials into two groups for each factor:
high dose (more than 14 Gy) versus low dose (less than or equal to
14 Gy); 50% or more of participants with classic CNV versus less
than 50% with classic CNV; and trials with no sham irradiation
versus those with sham irradiation. As the numbers of trials were
small and the purpose of this analysis was to compare treatment
effects only, we used odds ratios pooled using a fixed effect model.
We calculated an ’interaction effect’ (Altman 2003) i.e. compared
the pooled odds ratio in the two subgroups.
There were not enough data reported for other potential outcome
measures (growth of new vessels, contrast sensitivity and quality
of life) to enable a statistical analysis but these are discussed in the
results section.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies.
Finding the trials
The searches identified 149 reports. A further two potentially rel-
evant reports were identified by subsequent electronic searching
carried out for another project. We obtained full copies of 28
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reports which referred to 23 potentially relevant studies. We ex-
cluded 12 of these trials largely because the treatment groups were
not randomly allocated (see ’Characteristics of excluded studies’
table). A total of 11 trials were considered suitable for inclusion in
the review (see ’Characteristics of included studies’ table). For the
excluded studies the authors did not use the word “randomised” ie
they had twogroups but one, for example, was retrospectively iden-
tified.The included studies all stated that they were randomised
controlled trials but did not always specify how they performed
the randomisation (see below).
Types of participants
The 11 trials randomised a total of 1078 people. The studies
took place in Germany (Anders 1998; Eter 2002; RAD 1999),
the Netherlands (Bergink 1998), USA (Char 1999; Ciulla 2002;
Marcus 2001), Japan (Kobayashi 2000), UK (Kacperek 2001;
SFRADS 2002) and Switzerland (Valmaggia 2002). In all studies
the mean age of participants was approximately 75 years and in
most studies the majority of participants were women (range from
38% to 64%).
All studies recruited participants with subfoveal CNV associated
with AMD. Most studies, with the exception of Anders 1998
and Kacperek 2001, classified the CNV lesion as classic, occult or
mixed. In most trials the percentage of participants with classic or
predominantly classic CNV ranged between 37% and 57% (Table
2); in Marcus 2001 a lower percentage of participants with classic
CNV was recruited (12%).
Two studies did not specify visual acuity criteria for entry to the
trial (Eter 2002; Valmaggia 2002). Most studies specified that
eligible participants should have a worst visual acuity in the study
eye, usually between 6/60 and 6/120 (Anders 1998; Bergink 1998;
Ciulla 2002; Kacperek 2001; Marcus 2001; RAD 1999; SFRADS
2002); two studies did not specify a worst acuity (Char 1999;
Kobayashi 2000). Four studies specified that there should be some
visual loss, usually to 6/12 or less (Anders 1998; Char 1999; Ciulla
2002; Kobayashi 2000).
Types of intervention
Table 1 shows the dosage of radiotherapy applied in the different
studies. The dosage ranged from 24 Gy (four fractions of 6 Gy)
(Bergink 1998) to 7.5 Gy (one fraction) (Char 1999). Seven of
the studies gave no treatment to the control group (Anders 1998;
Bergink 1998; Char 1999; Eter 2002; Kacperek 2001; Kobayashi
2000; SFRADS 2002); three studies used sham irradiation (Ciulla
2002; Marcus 2001; RAD 1999) and one study used very low-
dose irradiation (1 Gy) (Valmaggia 2002).
Types of outcome measures
In all studies the primary outcome was visual acuity. In most cases
this was measured using the ETDRS chart or equivalent logMAR
chart. The exception to this was Bergink 1998 where Snellen acu-
ity was measured. Most studies considered some aspect of the clin-
ical progression of CNV such as area of CNV (Kobayashi 2000;
Valmaggia 2002) and appearance of the fundus on fluorescein
angiography (Marcus 2001; RAD 1999). Near vision (SFRADS
2002) and reading ability (Valmaggia 2002) were also consid-
ered. Two studies specifically considered safety (Kobayashi 2000;
SFRADS 2002).
Risk of bias in included studies
Table 3 shows the results of assessment of study quality.
In four studies (Kobayashi 2000; Marcus 2001; RAD 1999;
SFRADS 2002) trial reports indicated that randomisation had
been executed properly, that is, an unpredictable sequence of treat-
ment allocation was concealed properly from people recruiting
participants into the trial.
Studies that did not perform sham irradiation (Anders 1998;
Bergink 1998; Char 1999; Eter 2002; Kacperek 2001; Kobayashi
2000; SFRADS2002)were at greater risk of performance biaswith
participants and providers in general being aware of the treatment
group. However, in three of these studies efforts were made to
mask the outcome assessor to treatment group (detection bias)
(Char 1999; Kobayashi 2000; SFRADS 2002).
Follow-up rates were not described clearly in three studies (Bergink
1998; Char 1999; Kacperek 2001) and were slightly lower in the
control group in a further two studies (Kobayashi 2000; Marcus
2001). In one study (SFRADS 2002) a strictly intention-to-treat
analysis was not performed as one patient randomised to the con-
trol group received treatment and was analysed in the treatment
group. However, this was unlikely to have had a major impact on
the results of the study. None of the authors included people lost
to follow up in the analyses.
Effects of interventions
Primary outcomes
Data on visual acuity were not available in a form suitable for
inclusion in the review for two studies (Eter 2002; Kacperek
2001). In Eter 2002 45 eyes of 45 patients were assigned in a
ratio of 2:1 to either radiation treatment (20 Gy in 10 fractions)
or observation. There were no statistically significant differences
between treatment and control groups six months after treatment.
InKacperek 2001 38peoplewere treatedwith radiotherapy (18Gy
in 4 fractions) and compared to 28 people who were not treated.
At 12 months visual acuity was measured on 28 participants in
the treatment group and 20 in the control group. Participants in
the control group had lost more vision than the treatment group
(Mann Whitney test p = 0.028).
Follow up at six months
Three trials provided data on the primary outcome (three or more
lines visual acuity lost) at six months (Marcus 2001; SFRADS
2002; Valmaggia 2002). There was considerable inconsistency in
trial results. The I2 value (percentage of total variation across stud-
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ies that was due to heterogeneity rather than chance) (Higgins
2003) was 59.2%. The relative risk of losing three or more lines six
months after treatment varied from 0.40 (95% CI 0.18 to 0.88)
(Valmaggia 2002) to 1.06 (95% CI 0.71 to 1.57)(Marcus 2001).
There was less, but still substantial, heterogeneity in the outcome
six or more lines visual acuity lost (I2 = 42.6%) with the relative
risk varying from 0.07 (95% CI 0.0 to 1.11) (Valmaggia 2002) to
0.83 (95% CI 0.47 to 1.46) (SFRADS 2002).
Follow up at 12 months
Six trials provided data on visual acuity outcomes at 12 months
(Bergink 1998; Char 1999; Marcus 2001; RAD 1999; SFRADS
2002; Valmaggia 2002). Again there was considerable inconsis-
tency in trial results for the outcome of three or more lines visual
acuity lost (I2 = 59.0%) with the relative risk varying from 0.37
(95%CI 0.15 to 0.90) (Char 1999) to 1.22 (95%CI 0.91 to 1.62)
(Marcus 2001). There was less inconsistency for the outcome of
six or more lines visual acuity lost (I2 = 43.3%) with the relative
risk ranging from 0.21 (95% CI 0.07 to 0.68) (Bergink 1998) to
1.23 (95% CI 0.56 to 2.68) (Marcus 2001).
Follow up at 24 months
Three trials provided data on visual acuity outcomes at 24 months
(Kobayashi 2000; SFRADS 2002; Valmaggia 2002). There was
considerable inconsistency in trial results for the outcome of three
or more lines lost (I2 = 58.3%). However, in contrast to previous
follow up times and outcomes there was no inconsistency in trial
results for the outcome of six or more lines lost (I2 = 0%). The
pooled relative risk was 0.76 (95% CI 0.58 to 1.01). This result
approached statistical significance. Using a fixed effect model the
relative risk was 0.75 (95% CI 0.56 to 0.99) which was marginally
statistically significant (p = 0.04).
Visual acuity as a continuous outcome
Not all trials reported visual acuity outcomes in a dichotomous
format. In order to include data from the trials that did not, we also
collected data on logMAR visual acuity as a continuous variable.
These data were available for most trials at 12 months, either as
mean visual acuity at follow up or change in visual acuity since the
start of the trial. There was less heterogeneity in these outcomes.
For example, for the trials reporting change in visual acuity, the
I2 value was 12.2%. The pooled weighted mean difference was
0.02 (95% CI -0.06 to 0.11). These results were consistent with a
mean change in visual acuity of -0.06 (less than one line of visual
acuity in favour of the treated group) to 0.11 (approximately one
line of visual acuity in favour of the control group).
Sensitivity analysis
With only 11 trials included in the review and only some of these
trials providing data for some outcomes our ability to determine
the causes of the heterogeneity or inconsistency between trials was
limited. Using the factors prespecified in the protocol (dosage and
type of CNV) and one factor not prespecified in the protocol
(sham irradiation in the control group) we performed stratified
analyses for the visual acuity outcome (three or more lines lost) at
12 months (because this was the time period for which most data
were available) (see Table 4). There were no statistically significant
interactions. There was some indication that trials with no sham
irradiation reported a greater effect of treatment as did trials with
a greater percentage of participants with classic CNV. There was
little evidence for any effect of dosage.
Secondary outcomes
Our secondary outcome measures included change in membrane
size and contrast sensitivity. Of the trials that specifically studied
change in lesion size a beneficial outcome for treatment was found
by one (Kobayashi 2000).Nodifference in the growth rate between
treatment and controls were reported by four trials (Bergink 1998;
Char 1999; Marcus 2001; Valmaggia 2002). Of the trials that
specifically studied changes in contrast sensitivity, SFRADS 2002
reported a statistically significant difference in the loss of 0.3 log
units of contrast sensitivity in favour of treatment at 24 months
but not 3months. No statistically significant difference in contrast
sensitivity between treated and control groups were reported by
Marcus 2001.
Adverse effects
The incidence of adverse events was low in all the trials reviewed.
Three trials found slightly higher rates of cataract progression in
the treatment groups but this was not statistically significant (
Kobayashi 2000; Marcus 2001; RAD 1999).
There were no reported cases of radiation retinopathy, optic neu-
ropathy or the development of malignancy. However, the duration
of follow up was likely to be too short to detect this. Given the
mean age of participants this may not be a major concern.
Although there was an overall beneficial effect for treatment with
regard to vision Bergink 1998 reported a drop in central vision
with a loss of three or more lines in a substantial proportion of
patients in the treatment group. This was not reported by trials
using standard fractions (2 Gy) in the treatment protocol.
Other complications reported in the treatment group included
one case of rhegmatogenous retinal detachment and one case of
a large non-clearing vitreous haemorrhage (Marcus 2001); tran-
sient conjunctival injection in two participants (Kobayashi 2000);
and transient disturbance of the precorneal tear film, found to be
significant (SFRADS 2002).
D I S C U S S I O N
We identified 11 trials of the effect of radiotherapy on neovascu-
lar AMD, which randomised 1078 participants. Not all of these
trials could be included in each of our planned analyses because
of differences in the way outcomes were presented and follow-up
times.
There was considerable clinical and statistical inconsistency be-
tween trials. This heterogeneity meant that we were unable to
present a pooled estimate of treatment effect. Most trials found
effects that favoured treatment, but these were not always signif-
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icant. The exception was Marcus 2001 which consistently found
non-significant effects that favoured the control group. It is diffi-
cult to ascertain why this trial should be different but it had sham
irradiation in the control group and a very low percentage of par-
ticipants with classic CNV (12%).
With only 11 trials in the review and differences between trials in
terms of outcome reporting it was difficult to explore the sources
of heterogeneity. Subgroup analyses comparing groups of trials
with different attributes (i.e. low versus high dosage; low versus
high percentage with classic CNV; and sham irradiation versus
observation of the control group) did not reveal any statistically
significant interactions. With small numbers of trials in each sub-
group (range two to four) this was not surprising.
It is encouraging that therewere no significant adverse effects noted
with up to 20 Gy of radiotherapy deployed in 2 Gy fractions. The
occurrence of severe visual loss in some treated patients receiving
24 Gy in larger fractions questions the safety of higher doses.
Higher doses of radiation are associated with greater morbidity
such as radiation retinopathy and optic neuropathy. Given the
lack of a clear benefit of higher doses it cannot be assumed that
these may be used safely in clinical practice. The long-term risk to
the fellow eye from collateral radiation exposure also needs to be
determined.
Neovascular AMD is a heterogenous disease with variation in
CNV composition and disease presentation. Differences in lesion
composition, size and time in the natural history at presentation
may be a source of variability when assessing treatment outcome
among the different trials. Evidence from the TAP (TAP Study
1999) and VIP (Bressler 2002) trials showed that many people
with minimally classic (less than 50% classic) and occult with no
classic lesions had relatively good natural history. Despite present-
ing as large lesions, they maintained reasonably good visual acuity
throughout 24 months follow up without treatment. In contrast,
the majority of predominantly classic (more than 50% classic) le-
sions were four disc areas or less and were more likely to present
with lower visual acuity.
Kobayashi 2000 found a significant treatment benefit in partici-
pants with smaller CNV (less than 1.5mm2) with regard to smaller
increase in lesion size and significantly smaller decrease in Log-
MAR visual acuity for over two years. They also found that there
was no significant difference in visual outcome in participants with
larger CNV (more than 1.5 mm2). In contrast, Marcus 2001 did
not find lesion size (less than one to more than six disc areas) de-
termined treatment outcome.When the composition of the lesion
was considered, Bergink 1998 and Kobayashi 2000 found a better
treatment outcome for occult lesions. SFRADS 2002 suggested
that one possible reason for the negative outcome in their trial
was the predominance of wholly classic and predominantly clas-
sic subgroups. This finding was not supported by the other trials
included in this review.
The value of radiotherapy in the treatment of neovascular AMD
must be considered against other therapeutic options that are avail-
able. The present treatment of choice for predominantly classic
CNV is photodynamic therapy (PDT) with verteporfin. Alterna-
tives to PDT may have value in the treatment of lesions that are
not responsive to PDT. If radiotherapy, with its potential risk of
systemic morbidity and exposure to the fellow eye, is to be used
as a treatment it needs to be considered against other modalities
which do not carry the same risks.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Considerable clinical and statistical heterogeneity between pub-
lished trials of radiotherapy for AMD mean that we cannot draw
any conclusions as to treatment effect. It is possible that a moder-
ate treatment benefit from radiotherapy exists. The results of this
review do not currently support a role for external beam radio-
therapy in people with neovascular AMD.
Implications for research
Future trials should have a sufficient sample size to detect mod-
erate effects and should report data on visual acuity outcomes so
as to enable their inclusion in systematic overviews. Consistent
reporting of data on factors such as lesion size and composition
would also facilitate synthesis. Adequate masking of the treatment
groups should be considered a priority. It is possible that radio-
therapy may have a role as adjunctive treatment in conjunction
with anticipated pharmacological treatments. However, given the
recent evidence that most lesions are amenable to treatment with
PDT if identified at a smaller lesion size, trials evaluating radio-
therapy against PDT are warranted before radiotherapy can be
widely used.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Anders 1998
Methods Single centre.
Allocation: not stated.
Masking: participant - no; provider - no; outcome - no.
Exclusions after randomisation:
not stated
Participants Country: Germany.
Number randomised: 76.
Mean age: 77.7.
Sex: 67% women.
Inclusion Criteria: 50+ years; visual acuity decrease (0.05 and 0.5); angiographically proven CNV.
Exclusion criteria: previous laser photocoagulation to macula; previous radiation; other eye disease
Interventions Treatment: 12 Gy (6 x 2 Gy).
Control: observation.
Duration: 8 days
Outcomes Visual acuity, near and distance; FFA.
Notes
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Bergink 1998
Methods Single centre.
Allocation: not stated.
Masking: participant - no; provider - no; outcome - no.
Exclusions after randomisation: 3.
Participants Country: Netherlands.
Number randomised: 74.
Mean age: 74.
Sex: 56% women.
Inclusion criteria: 55+ years; visual acuity 20/200 or better; angiographically proven CNV; clinical signs
of ARM; informed consent.
Exclusion criteria: previous laser photocoagulation to macula; radiation for ear nose and throat or brain
disease; diabetes
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Bergink 1998 (Continued)
Interventions Treatment: 24 Gy (4 x 6 Gy).
Control: observation.
Duration: 21 days.
Outcomes Visual acuity (Snellen); Doubling of CNV size (FFA).
Notes
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Char 1999
Methods Single centre.
Allocation: not stated.
Masking: participant - no; provider - no; outcome - unclear (yes for FFA).
Exclusions after randomisation:
not stated
Participants Country: USA.
Number randomised: 27.
Mean age: 76.
Sex: 52% women.
Inclusion criteria: Subfoveal CNV secondary to AMD with visual acuity less than 20/40.
Exclusion criteria:
Interventions Treatment: 7.5 Gy.
Control: observation.
Duration: one day
Outcomes Visual acuity (ETDRS chart).
Notes
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
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Ciulla 2002
Methods Single centre.
Allocation: not stated.
Masking: participant - yes; provider - yes; outcome - yes.
Exclusions after randomisation:
not stated
Participants Country: USA.
Number randomised: 37.
Median age: 71.
Sex: 38% women.
Inclusion criteria: Subfoveal CNV due to AMD; visual impairment of affected eye less than 6 months
duration; best-corrected VA of affected eye < = 20/40 and > = 20/400.
Exclusion criteria: Unable to maintain steady fixation; preexisting retinal eye disease or media opacity; no
informed consent
Interventions Treatment: 16 Gy (2 x 8 Gy).
Control: sham irradiation (not described).
Duration: 2 days
Outcomes Visual acuity (ETDRS chart).
Notes
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
Eter 2002
Methods Multicentre: 3 centres.
Allocation: central telephone; blocked by centre.
Masking: participant: no; provider: no; outcome: no.
Exclusions after randomisation: 3 treatment, 1 control
Participants Country: Germany.
Number randomised: 45.
Median age: 74.
Sex: 53% women.
Inclusion criteria: age 45+ years; classic/occult CNV; informed consent; no prior radiation treatment to
head; no vascular eye disease; no prior treatment of AMD.
Exclusion criteria:
Interventions Treatment: 20 Gy (10 x 2 Gy).
Control: observation.
Duration: one week
Outcomes Visual acuity (logarithmic chart).
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Eter 2002 (Continued)
Notes
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Kacperek 2001
Methods Single centre.
Allocation: unclear.
Masking: participant - no; provider - no; outcome - no.
Exclusions after randomisation:
not stated
Participants Country: UK.
Number randomised: 66.
Mean age: 76 years.
Sex:
Inclusion criteria: Aged 50+ with subfoveal CNV (classic) and evidence of AMD e.g. drusen, VA>6/60.
Exclusion criteria: diabetes, severe hypertension and retinal vascular disease, myopia
Interventions Treatment: 18 Gy (4 x 4.5 Gy).
Control: observation.
Duration:4 days
Outcomes Visual acuity
Notes
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Kobayashi 2000
Methods Single centre.
Allocation: computer generated.
Masking: participant - no; provider - yes; outcome - unclear (yes for FFA).
Exclusions after randomisation:
not stated
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Kobayashi 2000 (Continued)
Participants Country: Japan.
Number randomised: 101.
Mean age: 72.
Sex: 64% female.
Inclusion criteria: 60+ years; unsuitability for laser under macular photocoagulation criteria; three or less
months of new or progressive CNV; visual acuity 20/50 or worse.
Exclusion criteria: pre-existing ocular disease (glaucoma, severe myopia, chronic inflammation, neoplasia)
; diabetes; uncontrolled hypertension; known life-threatening disease
Interventions Treatment: 20 Gy (10 x 2 Gy).
Control: observation.
Duration: 14 days.
Outcomes Visual acuity (ETDRS); area of CNV (FFA); safety.
Notes
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
Marcus 2001
Methods Single centre.
Allocation: computer generated; blocked.
Masking: participant - yes; provider - yes; outcome - yes.
Exclusions after randomisation:
not stated
Participants Country: USA.
Number randomised: 83.
Mean age: 76.
Sex: 61% female.
Inclusion criteria: active subfoveal CNV secondary AMD; >48 years of age; visual acuity > / = 20/400;
clinical and angiographic evidence of a choroidal neovascular membrane, which is itself or its contiguous
blood involving the centre of the foveal avascular zone.
Exclusion criteria: previous laser treatment; choroidal neovascularisation due to other causes; retinal vas-
cular diseases e.g. diabetes; previous ocular, orbital or periorbital radiation; likely candidates for chemo-
therapeutic agents
Interventions Treatment: 14 Gy (7 x 2 Gy).
Control: 1 sham treatment.
Duration: 7 working days.
Outcomes Visual acuity (ETDRS); contrast sensitivity; appearance of fundus (FFA and photography)
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Marcus 2001 (Continued)
Notes Patients with subfoveal choroidal neovascular membranes who were eligible for subfoveal laser according
to macular photocoagulation study guidelines were offered laser versus radiation or observation versus
radiation (this study)
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
RAD 1999
Methods Multicentre: 9 centres.
Allocation: computer generated.
Masking: participant - yes; provider - yes; outcome - yes.
Exclusions after randomisation:
Participants Country: Germany.
Number randomised: 205.
Mean age: 74.
Sex: 60% female.
Inclusion criteria: 50+ years old; written informed consent; exudative AMD with subfoveal involvement
and signs of ARM in the fellow eye; CNV 6+ disc diameters in size; visual acuity 20/320 or better in study
eye; symptoms for six months or less.
Exclusion criteria: ocular disease that could compromise the visual acuity in the study eye; haemorrhage;
previous macular photocoagulation or PDT; history of antiangiogenic drugs
Interventions Treatment: 16 Gy (8 x 2 Gy).
Control: 8 x 0 Gy.
Duration: 10 days.
Outcomes Visual acuity (ETDRS); FFA and fundus photography.
Notes
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
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SFRADS 2002
Methods Multicentre: 3 centres.
Allocation: central telephone; blocked by centre.
Masking: participant: no; provider: no; outcome: yes.
Exclusions after randomisation: 3 treatment, 1 control
Participants Country: UK.
Number randomised: 203.
Mean age: 75.
Sex: 57% female.
Inclusion criteria: Aged 60+; subfoveal CNV; 20/200 or better in study eye.
Exclusion criteria: Inability to give informed consent; late leakage of indeterminate origin; blood under
geometric centre of the fovea; other ocular disease; diabetes; other trials; prior radiotherapy
Interventions Treatment: 12 Gy (6 X 2 Gy).
Control: observation.
Duration:
Outcomes Visual acuity (ETDRS chart); near vision (Bailey-Lovie chart); radiation-associated problems
Notes
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
Valmaggia 2002
Methods Single centre.
Allocation: not stated.
Masking: participant - yes; provider - yes; outcome - yes.
Exclusions after randomisation:
no stated
Participants Country: Switzerland.
Number randomised: 161.
Mean age - 75.
Sex: 58% female.
Inclusion criteria: Symptoms of reduced vision, central central scotoma or metamorphopsia.
Exclusion criteria: foveal haemorrhage; severe haemorrhage impeding measurement of CNV; PED; other
ocular disease (glaucoma, severe myopia, diabetic retinopathy)
Interventions Treatment: 8 Gy (4 X 2 Gy) or 16 Gy (4 X 4 Gy).
Control: 1 Gy (4 X 0.25 Gy).
Duration: 4 days.
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Valmaggia 2002 (Continued)
Outcomes Visual acuity (logMAR chart); reading ability; CNV size (FFA/indocyanine green); radiation-associated
side effects (ocular irritation, conjunctivitis, cataract, radiation retinopathy, radiation optic neuropathy)
Notes
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Abbreviations:
AMD - age-related macular degeneration
ARM - age-related maculopathy
CNV - choroidal neovascularisation
ETDRS - Early Treatment of Diabetic Retinopathy Study
FFA - fundus fluorescein angiography
Gy - gray
PDT - photodynamic therapy
PED - pigment epithelial detachment
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Bergink 1995 Treatment groups probably not randomly allocated.
Brown 1997 Treatment groups allocated sequentially.
Eter 2001 One eye treated and fellow eye served as a control. Unclear whether first eye treated randomly
Honjo 1997 Treatment groups probably not randomly allocated.
Mandai 1998 Treatment groups probably not randomly allocated.
Mandai 2000 Retrospective study - groups not allocated randomly.
Matsuhashi Treatment groups not allocated randomly. Control group consisted of people who had refused radiation or laser
treatment
Matsuhashi 1996 Treatment groups not allocated randomly
Postgens 1997 Retrospective study - groups not allocated randomly.
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(Continued)
Saric 2001 Control group consisted of patients who had refused treatment
Taniguchi 1996 Treatment and control groups probably not randomly allocated
Tholen 2000 This study initially began as an RCT but the trial was stopped because of radiogenic complications in the high
dose group (36Gy). The study was continued as a non-randomised study and the reports did not distinguish
randomised and non-randomised comparisons
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